AGMB — Agomab Therapeutics NV Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Agomab Therapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | ||||
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 22.6 | 31.2 | 48 | 59.3 |
| Operating Profit | -22.6 | -31.2 | -48 | -59.3 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -10.8 | -12 | -46.3 | -62.5 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -8.14 | -11.4 | -46.3 | -62.5 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -8.14 | -11.4 | -46.3 | -62.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -8.14 | -11.4 | -46.3 | -62.5 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.167 | -0.234 | -0.949 | -1.28 |